Coprescription of triptans with potentially interacting medications: A cohort study involving 240268 patients

Headache

Volumn 43, Issue 1, 2003, Pages 44-48

  Tepper, Stewart ^a,b   Allen, Christopher ^c   Sanders, David ^c   Greene, Alison ^d   Boccuzzi, Stephen ^d  

^a NEW ENGLAND CENTER FOR HEADACHE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Merck and Co Inc ^*

Author keywords

Drug interaction; Migraine; Triptan

Indexed keywords

BROMOCRIPTINE; CIMETIDINE; CLARITHROMYCIN; CLOTRIMAZOLE; CYCLOSPORIN; ELETRIPTAN; ERGOT ALKALOID; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; INDINAVIR; ITRACONAZOLE; JOSAMYCIN; KETOCONAZOLE; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; NELFINAVIR; NORSERTRALINE; PAROXETINE; PROPRANOLOL; RITONAVIR; RIZATRIPTAN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; UNINDEXED DRUG; VERAPAMIL; ZOLMITRIPTAN;

ADULT; AGED; ARTICLE; COMORBIDITY; DEPRESSION; DRUG CONTRAINDICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; PRESCRIPTION; PRIORITY JOURNAL; SEROTONIN SYNDROME;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MONOAMINE OXIDASE INHIBITORS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; SEROTONIN AGONISTS;

EID: 0037253081     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2003.03007.x     Document Type: Article

References (13)

1. Lipton RB, Stewart WF. Migraine headaches: epidemiology and comorbidity. Clin Neurosci. 1998;5:2-9.
2. U.S. Census data. http://www.census.gov/ftp/pub/population/www.
3. U.S. labeling information for naratriptan, rizatriptan, sumatriptan and zolmitriptan. 2001 Physician's Desk Reference. Montvale, NJ: Thomas Healthcare; 2001.
4. Summaries of product characteristics for eletriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan. Electronic Medicines Compendium. http://emc.vhn.net.
5. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998;38:389-430.
6. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84-112.
7. Tepper SJ, Ward T. Patient reported tablet utilization of zolmitriptan and sumatriptan. Headache. 1998;38:408.
8. Pascual J, Frias J, Fite B, Casado E, Barbero A, Beneytez A, Lopez-Gil A. Prospective study on triptan tablet consumption per attack in Spain. Cephalalgia. 2000;20;411.
9. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology. 2000;55:629-635.
10. Patten SB. Major depression prevalence in Calgary. Can J Psychiatry. 2000;45:923-926.
11. Putnam GP, O'Quinn S, Bolden-Watson CP, Davis RL, Gutterman DL, Fox AW. Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. Cephalalgia. 1999;19:668-675.
12. Hettiarachchi J, Turrell K. Concomitant eletriptan and selective serotonin reuptake therapy for migraine patients: a review of seven clinical studies. Cephalalgia. 2001;21:431.
13. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Safety. 1999;20:277-287.